News | August 19, 2024
Zydus Lifesciences to scale up US specialties business
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Imfinzi also recommended for patients with mismatch repair deficient disease
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Subscribe To Our Newsletter & Stay Updated
